EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure

A Cremer, A Mansour, T Lobaton, P Bossuyt, J Rahier, F Baert, O Dewit, E Macken, A Vijverman, P Van Hootegem, F Mana, B Willandt und 16 weitere

Acta Gastro Enterologica Belgica · 2025

DOI: 10.51821/88.3.14064 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Acta Gastro Enterologica Belgica, 2025. Verfasst von A Cremer und 27 weiteren Autor:innen. Beteiligte Einrichtung: Erasme University Hospital, Department of Gastroenterology, Brussels, Belgium. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Piperidines, Antibodies, Monoclonal, Humanized, Pyrimidines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims: Tofacitinib has expanded treatment options for moderate-to-severe ulcerative colitis (UC). Longterm real-world data on its efficacy and safety remain limited, particularly in multi-refractory populations. This study evaluated the real-world effectiveness and safety of tofacitinib in Belgian UC patients with prior exposure to anti-TNF and vedolizumab. Patients and methods: This retrospective multicentric observational study included consecutive adult UC patients from 26 Belgian centers who initiated tofacitinib through an early access program (November 2018-August 2019). Data were prospectively collected. Primary endpoint was clinical remission (partial adapted Mayo score≤1) at the end of follow-up (predefined as week 52). Secondary endpoints included endoscopic outcomes, treatment retention rate, colectomy-free survival, and adverse events (AEs). Results: Seventy-five patients (59% men, median age 44 years) were included, with a median treatment duration of 45 weeks (IQR:19-51). At baseline, 96% had prior anti-TNF and 97% antiintegrin exposure, while 56% were on concomitant steroids. Clinical remission was achieved by 43% at the end of follow-up. Endoscopic response and remission were observed in 37% and 9% of patients, respectively. Fecal calprotectin

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativePiperidinesAntibodies, Monoclonal, HumanizedPyrimidinesProtein Kinase InhibitorsHumansMaleFemaleAdultRetrospective StudiesBelgiumMiddle AgedTreatment OutcomeRemission InductionGastrointestinal AgentsTumor Necrosis Factor Inhibitors

Stichwörter der Autor:innen

JAK inhibitorefficacyinflammatory bowel disease

Substanzen

tofacitinibvedolizumabPiperidinesAntibodies, Monoclonal, HumanizedPyrimidinesGastrointestinal AgentsTumor Necrosis Factor InhibitorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Erasme University Hospital, Department of Gastroenterology, Brussels, Belgium.
  • University Hospital Ghent, Department of Gastroenterology, Ghent, Belgium.
  • Imelda General Hospital, Department of Gastroenterology, Bonheiden, Belgium.
  • CHU UCL Namur, Department of Gastroenterology, Yvoir, Belgium.
  • AZ Delta, Department of Gastroenterology, Roeselare, Belgium.
  • CHU Saint-Luc, Department of Gastroenterology, Brussels, Belgium.

Zitieren

APA

Cremer, A., Mansour, A., Lobaton, T., Bossuyt, P., Rahier, J., Baert, F., Dewit, O., Macken, E., Vijverman, A., Van Hootegem, P., Mana, F., Willandt, B., Humblet, E., D'Heygere, F., Verreth, A., El Nawar, A., Coenegrachts, J., Dewit, S., De Coninck, S., …, & Franchimont, D. (2025). Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure. Acta Gastro Enterologica Belgica. https://doi.org/10.51821/88.3.14064

Vancouver

Cremer A, Mansour A, Lobaton T, Bossuyt P, Rahier J, Baert F, et al. Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure. Acta Gastro Enterologica Belgica. 2025. doi:10.51821/88.3.14064

BibTeX
@article{Cremer2025,
  author = {Cremer, A and Mansour, A and Lobaton, T and Bossuyt, P and Rahier, J and Baert, F and Dewit, O and Macken, E and Vijverman, A and Van Hootegem, P and Mana, F and Willandt, B and Humblet, E and D'Heygere, F and Verreth, A and El Nawar, A and Coenegrachts, J and Dewit, S and De Coninck, S and Schoofs, N and Delen, S and Dutre, J and Thienpont, C and Vanden Branden, S and Staessen, D and Croonen, C and Vieujean, S and Franchimont, D},
  title = {Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure},
  journal = {Acta Gastro Enterologica Belgica},
  year = {2025},
  doi = {10.51821/88.3.14064}
}
Kostenlos starten →